Surgical management of dermatofibrosarcoma protuberans.

Dermatofibrosarcoma protuberans (DFSP) is an uncommon, locally aggressive cutaneous malignancy. Complete resection is the primary treatment but there is debate over the optimal method. Wide local excision was traditionally the standard of care; however, National Comprehensive Cancer Network guidelines now recommend Mohs micrographic surgery as the preferred approach. Medical therapy with imatinib can be used in advanced or unresectable disease. This review will discuss the current management of DFSP, focusing on optimal surgical approach.

Analysis of microsatellite instability using Promega panel in dermatofibrosarcoma protuberans.

Dermatofibrosarcoma protuberans (DFSP) is a rare neoplasm derived from fibroblasts. Although the frequency of microsatellite instability (MSI) in skin cancer is reported to be less than 5%, there is only one report of the status of MMR in DFSP. The only analytical report of microsatellite stability in which Promega panel is not used, showed that the frequency of MSI-high, MSI-low and microsatellite stable (MSS) cases was 13.9% (5/36), 16.7% (6/36) and 69.4% (25/36), respectively. Thus, the aim of this study was to evaluate the status of MMR in 36 patients with DFSP diagnosed at Kumamoto University. MSI analysis using the Promega panel showed that all cases were MSS, which indicated the absence of MSI in DFSP. This result indicates that the status of MMR may not be useful for the potential therapeutic application of pembrolizumab and the pathogenesis of DFSP may not involve MSI.

Establishment of novel patient-derived models of dermatofibrosarcoma protuberans: two cell lines, NCC-DFSP1-C1 and NCC-DFSP2-C1.

Dermatofibrosarcoma protuberans (DFSP) is a common type of dermal sarcoma, characterized by the presence of the unique collagen type I alpha 1 chain (COL1A1)-PDGFB translocation, which causes constitutive activation of the platelet-derived growth factor ß (PDGFB) signaling pathway. Patients with DFSP exhibit frequent local recurrence, and novel therapeutic approaches are required to achieve better clinical outcomes. Patient-derived cancer cell lines are essential in the preclinical research. Here, we established novel patient-derived DFSP cell lines from two patients with DFSP and designated these cell lines NCC-DFSP1-C1 and NCC-DFSP2-C1. Tumors of the two patients with DFSP had COL1A1-PDGFB translocations with distinct COL1A1 breakpoints, e.g., in exons 33 and 15, and the translocations were preserved in the established cell lines. NCC-DFSP1-C1 and NCC-DFSP2-C1 cells exhibited similar morphology and limited capability of proliferation in vitro, forming spheroids when seeded on low-attachment tissue culture plates. In contrast, NCC-DFSP1-C1 cells had considerably higher invasive capability than NCC-DFSP2-C1 cells. Overall proteome contents were similar between NCC-DFSP1-C1 and NCC-DFSP2-C1 cells. Notably, in vitro screening studies identified anticancer drugs that showed antiproliferative effects at considerably low concentrations in the DFSP cell lines. Bortezomib, mitoxantrone, ponatinib, and romidepsin were more cytotoxic to NCC-DFSP1-C1 cells than to NCC-DFSP2-C1 cells. These cell lines will be useful tools for developing novel therapeutic strategies to treat DFSP.

Dermatofibrosarcoma protuberans: revisión de la literatura / Dermatofibrosarcoma protuberans: literature review

Dermatofibrosarcoma Protuberans (DFS-P) es una neoplasia de partes blandas y cutánea poco frecuente, de crecimiento superficial con tendencia a recurrir localmente y bajo potencial metastásico. Ocurre en personas de edad media, preferentemente en tronco y zonas proximales de extremidades. Requiere un alto grado de sospecha clínica, ya que inicialmente puede ser similar a una cicatriz hipertrófica o a un dermatofibroma. A continuación se realiza una revisión de la literatura sobre este tumor poco frecuente, con énfasis en las características clínicas y las opciones terapéuticas actualizadas según las guías 2010 de la National Comprehensive Cancer Network(NCCN).

Dermatofibrosarcoma protuberans (DFS-P) is a soft cutaneous neoplasm, pretty rare, with superficial growing, that tends to local recurrence. Usually it present at medium age, in trunk and the beginning of extremities. It is very difficult to diagnose at the beginning because its similarity with hypertrophic scar or dermatofibroma. We present a review in the literature of DFS-P, with emphasizing the early clinical manifestations and the different therapeutic agents recently approved by National Comprehensive Cancer Network (NCCN).

Nonmelanoma skin cancer.

This article provides readers with a comprehensive review of the evaluation and management of nonmelanoma skin cancers. Treatment recommendations are heavily based on the most recent guidelines from the National Comprehensive Cancer Network. Merkel cell carcinoma and dermatofibrosarcoma protuberans are also discussed. After reviewing this article, readers should be equipped with a better understanding of these entities and the current recommendations for their management.

Melanoma desmoplásico simulando un Dermatofibrosarcoma protuberans / Desmoplastic melanoma resembling a Dermatofibrosarcoma Protuberans

El melanoma desmoplásico fue descrito por Conley et al en 1971. Desde entonces se han publicado extensas series, sin embargo, son escasas las publicaciones hispanas. En realidad se trata de una rara variante de melanoma de difícil diagnóstico tanto clínico, porque ésta es inespecífica, como histopatológico, porque se trata de un tumor de células fusiformes sin diferenciación clara.Presentamos el caso de una varón de 44 años con una lesión en escápula izquierda que semejaba un dermatofibrosarcoma protuberans pero que en el estudio histopatológico se descubrió un melanoma desmoplásico.Se realiza una revisión de la literatura y se hace especial hincapié en las características histopatológicas que nos pueden orientar hacia un correcto diagnóstico (AU)